Nanyue was sold at a premium of 48%. The company announced on April 27, 2012, that after listing transfers and public bidding, 36% of Nanyue Pharmaceutical's shares held by the company were finally transferred to Hainan Hanson Investment for 182.1 million yuan. Compared with the initial listing and transfer reserve price of 123.4 million yuan, the premium reached 48%. The company will sign a “property rights transaction contract” with the transferee within 3 working days. Focus on your main business and move forward quickly. After the company changed its leadership, it strengthened its development strategy focusing on the traditional Chinese medicine health care field with “Guhan Health Essence” as the core, and continued to divest non-core assets. The successful transfer of shares in Nanyue Pharmaceutical finally resolved the Nanyue equity dispute that had plagued the company for many years, and obtained sufficient cash, which helped accelerate the nationwide promotion of the company's dominant variety of Guhan Health Essence. Guhan Health Essence has the potential to become a major health brand. The essence of ancient Han health is taken from the “Health Recipe”, a national treasure of China's health culture - the health secrets of the heyday of traditional Chinese medicine in the Han Dynasty. It has rich cultural heritage and health benefits, and is a nationally classified variety. However, more than 20 years of clinical application in Hunan have verified its exact efficacy, and it has won wide praise and recognition. With accurate health benefits, rich cultural heritage, and good market reputation, Guhan Health Essence has the potential to become a major health brand. The company has begun to increase the promotion of Guhan Health Essence: (1) Hunan Market: Currently, the revenue before tax in the province is close to 300 million yuan. The company will further increase the construction of Guhan health specialty stores and counter systems in the next two years, launch public service advertisements, hold special events, stabilize market prices, establish brand image, maintain customer relationships, and drive continuous sales growth; (2) National market: The company plans to launch a public service advertisement for Guhan Health Essence in the first half of the year, while gradually boosting terminal sales through the layout of exclusive stores and terminals; (3): Acted by Three Kings Group, mainly in Hong Kong Sales will also gradually enter Southeast Asia and the global market. Profit forecast: It is estimated that the sale of Nanyue Pharmaceutical will bring about 100 million dollars in investment income to the company. We estimate that the company's 2012 EPS will reach 0.97, and the 2013-2014 EPS will be 0.58 and 0.78 respectively, regardless of investment income. The company's main business in 2012-2014 EPS is 0.45, 0.58 and 0.77, respectively, with growth rates of 32%, 28% and 33%, maintaining the company's “buy” rating. Risk warning: Guhan health essence marketing promotion falls short of expectations